<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073718</url>
  </required_header>
  <id_info>
    <org_study_id>2022-000535-23</org_study_id>
    <nct_id>NCT05073718</nct_id>
  </id_info>
  <brief_title>SARS-CoV-2 and Acetylsalicylic Acid (SARA)</brief_title>
  <acronym>SARA</acronym>
  <official_title>Efficacy of Low Dose Acetylsalicylic Acid in Preventing Adverse Maternal and Perinatal Outcomes in SARS-CoV-2 Infected Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario de Torrejón</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Infanta Leonor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eduardo Mondlane University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Central de Maputo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Geral de Mavalane</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Geral José Macamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barcelona Institute for Global Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SARS-CoV-2 infection in pregnancy is associated with an increased risk of adverse maternal&#xD;
      and perinatal outcomes. One explanation is that the infection might increase the existing&#xD;
      pregnancy-associated prothrombotic status, leading to a higher risk of placental and vascular&#xD;
      complications. Administration of low-dose acetylsalicylic acid (LDASA) has shown to improve&#xD;
      maternal and perinatal outcomes in women at high-risk of endothelial and placental&#xD;
      complications. However, there are no data on the effect of LDASA in preventing complications&#xD;
      in SARS-CoV-2- infected pregnant women. To reduce SARS-CoV-2- related complications in a&#xD;
      highly vulnerable group to the infection, we will carry out this randomized, double-blind,&#xD;
      placebo-controlled multicentre trial in 400 SARS-CoV-2-infected pregnant women. The study&#xD;
      main objective is to evaluate the efficacy and safety of LDASA administered up to 36 weeks of&#xD;
      gestation in SARS-CoV-2-infected pregnant women in reducing the incidence of adverse maternal&#xD;
      and perinatal outcomes. Pregnant women tested positive up to 32 weeks of gestation with a&#xD;
      SARS-CoV-2 rapid antigen or PCR test and agreeing to participate, will be randomised 1:1 to&#xD;
      receive daily LDASA (125 mg) or placebo up to 36 weeks of gestation and be followed-up until&#xD;
      delivery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blind placebo-controlled multicentre clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study tablets will be identically packaged in small boxes. All study personnel, investigators and the participants will remain blinded throughout the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of composite adverse maternal and perinatal adverse outcomes including miscarriage, foetal death, preeclampsia, maternal thromboembolic complications, placental abruption, preterm birth and small for gestational age.</measure>
    <time_frame>up to 37 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of SARS-CoV-2 infection and COVID-19 disease during pregnancy</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19-related admissions</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause admissions</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause outpatient attendances</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of symptoms-signs of COVID-19</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of preeclampsia</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal thromboembolic complications and placental abruption</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal mortality rate</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of histological placental abnormalities in SARS-CoV-2 infected pregnant women.</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>maternal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of preterm birth (&lt;37 weeks of gestational age)</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>embryo-foetal/infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of small for gestational age</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>embryo-foetal/infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of embryo and foetal losses (miscarriages and stillbirths)</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>embryo-foetal/infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of congenital malformations</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>embryo-foetal/infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse perinatal outcome</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>embryo-foetal/infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal morbidity</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>embryo-foetal/infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality rate</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>embryo-foetal/infant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>LDASA (n=200)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (n=200)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose acetylsalicylic acid</intervention_name>
    <description>In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.</description>
    <arm_group_label>LDASA (n=200)</arm_group_label>
    <other_name>125mg acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo (n=200)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women up to 32 weeks of gestational age&#xD;
&#xD;
          -  Aged 18 years or older*&#xD;
&#xD;
          -  Willing to deliver at the recruitment health facilities&#xD;
&#xD;
               -  In Mozambique, in case of age below 18 years, the participant will be asked for&#xD;
                  the assent and the informed consent will be given by the legal tutor in&#xD;
                  accordance with the national regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On regular ASA treatment for pre-eclampsia prevention&#xD;
&#xD;
          -  On long-term non-steroidal anti-inflammatory medication&#xD;
&#xD;
          -  Bleeding disorders, mainly haemophilia, hypoprothrombinaemia orVon Willebrand's&#xD;
             disease&#xD;
&#xD;
          -  History of hypersensitivity to ASA or to any of the excipients of the investigational&#xD;
             product.&#xD;
&#xD;
          -  History of peptic ulceration, including active, chronic or recurrent gastroduodenal&#xD;
             ulcer; recurrent gastric discomfort History of gastric bleeding or perforation after&#xD;
             treatment with aspirin or other non-steroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Inability to cooperate with the requirements of the study&#xD;
&#xD;
          -  Severe COVID-19 disease (with any of the following: respiratory rate &gt; 30 breaths/min;&#xD;
             severe respiratory distress; SpO2 ≤ 93% on room air; acute respiratory distress&#xD;
             syndrome; sepsis with acute organ dysfunction).&#xD;
&#xD;
          -  Treatment resistant hyperemesis gravidarum&#xD;
&#xD;
          -  Hypersensitivity to nonsteroidal anti-inflammatory drugs or to tartrazine&#xD;
             (cross-reaction) or to any of the excipients used in its composition.&#xD;
&#xD;
          -  Asthma.&#xD;
&#xD;
          -  Severe renal or hepatic insufficiency.&#xD;
&#xD;
          -  Nasal polyps associated with asthma that are induced or exacerbated by aspirin.&#xD;
&#xD;
          -  Severe COVID-19 disease (with any of the following: respiratory rate &gt; 30 breaths/min;&#xD;
             severe respiratory distress; SpO2 ≤ 93% on room air; acute respiratory distress&#xD;
             syndrome; sepsis with acute organ dysfunction).&#xD;
&#xD;
          -  Treatment resistant hyperemesis gravidarum&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Menéndez, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barcelona Institute for Global Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candelaria Serrano, Dr.</last_name>
    <phone>+34 691642368</phone>
    <email>candelaria.serrano@isglobal.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Stoeger, MSc</last_name>
    <email>linda.stoeger@isglobal.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Eduardo Mondlane</name>
      <address>
        <city>Maputo</city>
        <zip>257</zip>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Torrejón</name>
      <address>
        <city>Torrejón de Ardoz</city>
        <state>Madrid</state>
        <zip>28850</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Mozambique</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>February 28, 2023</last_update_submitted>
  <last_update_submitted_qc>February 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-COV2</keyword>
  <keyword>Acetylsalicylic acid</keyword>
  <keyword>Asprin</keyword>
  <keyword>ASA</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Perinatal</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

